Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx.
Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier ML, Faure-Dupuy S, Riedl T, Lange S, Wisskirchen K, Thiele F, Cheng CC, Yuan D, Leone V, Schmidt R, Hünergard J, Geisler F, Unger K, Algül H, Schmid RM, Rad R, Wedemeyer H, Levrero M, Protzer U, Heikenwalder M. Ringelhan M, et al. Among authors: kotsiliti e. JHEP Rep. 2024 Jun 6;6(10):101128. doi: 10.1016/j.jhepr.2024.101128. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39290403 Free PMC article.
EASL Congress 2024.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 Sep;21(9):606. doi: 10.1038/s41575-024-00971-8. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39103626 No abstract available.
Metastatic pancreatic cancer and the liver.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 Sep;21(9):606. doi: 10.1038/s41575-024-00972-7. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39103625 No abstract available.
Incretin-based therapies for liver disease.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 Aug;21(8):533. doi: 10.1038/s41575-024-00961-w. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38977817 No abstract available.
Bacteriophages and host inflammation in IBD.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 May;21(5):300. doi: 10.1038/s41575-024-00925-0. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38519791 No abstract available.
HCC genomic landscape in Chinese individuals.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 May;21(5):300. doi: 10.1038/s41575-024-00924-1. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38519790 No abstract available.
Seladelpar in primary biliary cholangitis.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 May;21(5):300. doi: 10.1038/s41575-024-00922-3. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38519788 No abstract available.
2023 FDA approvals in gastroenterology and hepatology.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 Apr;21(4):219. doi: 10.1038/s41575-024-00916-1. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38454155 No abstract available.
89 results